Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04159350 · ClinicalTrials.gov registry record · NA
Point-of-care Anorectal Testing to Predict Outcomes With Biofeedback Therapy: Clinical Trial
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 99
- Enrollment target
NCT04159350: Completed NA study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT04159350 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04159350, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
Study Summary
To prospectively evaluate the clinical utility of baseline anorectal function testing using a point-of-care device in predicting response of chronically constipated patients to physical therapy biofeedback training.
Primary Outcome
The Patient Assessment of Constipation-Symptoms (PAC-SYM) questionnaire is a short, easily-completed instrument for assessing global constipation symptoms. A total PAC-SYM score ranges from 0 to 48.
Interventions
- DEVICE Rectal Expulsion Device (RED) - Feasibility
- DEVICE Rectal Expulsion Device (RED) - Validation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2021-09-13 |
| Phase | NA |
What the finished NCT04159350 record still lists
NCT04159350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Rectal Expulsion Device (RED) - Feasibility is the first listed.
NCT04159350 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04159350 about?
NCT04159350 is a clinical study titled "Point-of-care Anorectal Testing to Predict Outcomes With Biofeedback Therapy: Clinical Trial". To prospectively evaluate the clinical utility of baseline anorectal function testing using a point-of-care device in predicting response of chronically constipated patients to physical therapy biofeedback training.
What is the current status of trial NCT04159350?
This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2020-06-15. Estimated completion is 2021-09-13.
What interventions are being tested in trial NCT04159350?
The interventions under investigation include: Rectal Expulsion Device (RED) - Feasibility (DEVICE), Rectal Expulsion Device (RED) - Validation (DEVICE).
Who is sponsoring clinical trial NCT04159350?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04159350's enrollment target sits among peer trials
99 920th of 2000 higher than 1,079 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI